CLINICAL

Evogen participates in the global clinical in vitro diagnostic (IVD) market which is valued at approximately $30 billion, of which the fastest growing segments are molecular diagnostics and point of care testing. The IVD market is segmented into the diagnosis and monitoring of specific areas such infectious diseases, critical care, genetics and cancer.

Evogen is developing molecular testing systems to serve the global market with key advantages in affordability, performance and turnaround time enabling everyone to have the genetic testing capability they need.

Beginning with the RA-24 HD-24, it will be an innovative instrument platform that enables ultra-rapid amplification together with 1multi-sample analysis detection in less time than current platforms, Evogen will expand its offering with additional platforms for integrated sample preparation and higher throughput.

The full Evogen solution is provided through the HyBeacons® probes which can be rapidly developed using proprietary single probes with multiple targets, rather than the more common single probe to single target combination.  This allows a more accurate and robust diagnostic assay.